Funding for this research was provided by:
National Institute of General Medical Sciences (P01GM051487, F32GM122334)
Life Sciences Research Foundation
Howard Hughes Medical Institute
Received: 29 January 2019
Accepted: 28 May 2019
First Online: 5 July 2019
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences, and Inari. J.A.D is a member of the board of directors at Johnson & Johnson, and has sponsored research projects supported by Pfizer, Inc. and Biogen. The remaining authors declare no competing interests.